Special Issue

Alphaviruses

Message from the Guest Editor

I am putting together a Special Issue entitled *Alphaviruses.* I would like to publish reviews or short articles written by yourself or your current or former post-doctoral fellows, students, or collaborators in this Special Issue. I would like to feature your most recent work and reviews on the following:

- Small molecule therapeutics, drug discovery, and medicinal chemistry;
- Antivirals, vaccines, and antibodies;
- Animal models;
- Detection methods, imaging methods, biosurveillance, and clinical isolates;
- Viroinformatics;
- Blood-brain barrier (BBB);
- Host-pathogen interactions;
- Effects on neurons, inflammation, and cytopathic effects;
- Structural biology;
- Enzymes.

I would like to highlight some of the more neglected areas of alphaviruses such as understanding their viral code, sequence-to-symptom patterns, host-pathogen interactions, therapeutic strategies, and even some modern methods of research such as machine learning and sequence analysis (viroinformatics) in order to inspire younger generations to pursue work in virology and to recognize that there are still challenging problems ahead.

Guest Editor

Dr. Patricia M. Legler Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375, USA

Deadline for manuscript submissions

closed (25 March 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/115401

Viruses Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/

viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



viruses



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).